News

reMYND’s transgenic hTauP301L model of Alzheimer’s disease displays progressive neuronal loss correlating with development of Tau pathology

29-03-2017
Neuronal loss, a pathological hallmark of Alzheimer’s disease, is recapitulated in reMYND’s transgenic human hTauP301L mouse model.

reMYND’s transgenic hTauP301L model of Alzheimer’s disease displays progressive astrocytosis and microgliosis correlating with development of Tau pathology

14-03-2017
The role of microglia and astrocytes in Alzheimer’s disease and how these contribute to neuronal loss has gained increased interest over the past years. This pathologically feature is recapitulated in reMYND’s transgenic APP, APPxPS1 and hTauP301S mouse models.

reMYND receives grants from Flanders and Europe to advance break-through treatments in Epilepsy and Alzheimer’s

14-03-2017
reMYND NV today announced that it has received two grants from Flanders and Europe to advance break-through treatments in Epilepsy and Alzheimer’s respectively. VLAIO, the Flemish agency for Innovation and Entrepreneurship, has provided a grant to assess therapeutics for epilepsy.

A novel transgenic mouse model showing the exacerbating interplay between Abeta- and Tau.P301S-driven pathology

10-06-2016
The interplay of Ab and Tau is still considered detrimental if not crucial for disease etiology and progression of Alzheimer’s Disease.

reMYND signs the Statement in support of animal research and a transparent approach

22-04-2016
Press release | reMYND, has joined with 21 other organisations from across the life sciences sector in signing up to a declaration on openness on animal research.

Pages